Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

To learn if pentoxifylline and vitamin E or pravastatin can reduce radiation-induced lymphedema/fibrosis.

开始日期2025-11-29

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT06912763

/ Not yet recruiting临床2期IIT

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.

开始日期2025-09-18

申办/合作机构-

NCT06998628

/ Recruiting临床2期IIT

Clinical Study Evaluating the Effect of Pentoxifylline as Anti Inflammatory in Patients With Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints

开始日期2025-07-02

申办/合作机构

Tanta University

100 项与己酮可可碱相关的临床结果

登录后查看更多信息

100 项与己酮可可碱相关的转化医学

登录后查看更多信息

100 项与己酮可可碱相关的专利（医药）

登录后查看更多信息

7,652

项与己酮可可碱相关的文献（医药）

2025-10-01·TISSUE & CELL

Targeting the p38MAPK/STAT3/NF-κB65 pathway modulates the hepatoprotective effect of pentoxifylline against sodium valproate-induced liver injury in rats; A study based on integrating network pharmacology and experiment validation

Article

作者: Alaa Mohamed Kamel, Gellan ; Hussein, Shaimaa

Sodium valproate (SVP) is frequently utilized in the treatment of epilepsy. Extended administration of SVP elevates the likelihood of hepatotoxicity. Pentoxifylline (PTX) functions as a nonselective phosphodiesterase inhibitor and is commonly utilized in the treatment of vascular conditions, exhibiting extensive antioxidant and anti-inflammatory properties. This research examined PTX's protective role in mitigating SVP-induced liver injury, clarifying the potential molecular mechanisms involved. SVP and PTX intersection targets were identified through network pharmacology. In addition, we conducted an in vivo experiment utilizing the SVP-induced liver injury model. Eighteen adult male rats were allocated to three groups, with the control group receiving oral normal saline. The SVP group was administered SVP (dissolved in normal saline) daily for 2 weeks. The PTX + SVP group was administered SVP in conjunction with PTX daily for two weeks. PTX hepatoprotective effect against SVP could include apoptosis, anti-inflammatory mechanisms, and various signaling pathways, such as NF-κB, STAT3, and MAPK, as indicated by the KEGG and GO enrichment analysis of the 272 common targets. We identified BCL2, IL6, and TNF as potential hub targets of PTX for liver injury treatment based on the construction of the PPI network. In vivo experiments demonstrated that PTX hindered MAPK P38/STAT3/NF-κB-related pathways' activation, diminished oxidative stress, apoptosis, and inflammatory response, and substantially ameliorated SVP-induced liver injury. The network pharmacology study concluded that the MAPK P38/STAT3/NF-κB pathway plays a role in PTX protective effect against SVP-induced liver injuries, as demonstrated by the in vivo experiment results.

2025-09-01·ENVIRONMENTAL POLLUTION

Validation of a large volume-solid phase extraction methodology for biotoxicity assessment of pharmaceuticals in aquatic organisms

Article

作者: Gómez-Canela, Cristian ; Moragrega-Knol, Emma ; Barata, Carlos ; Romero-Alfano, Irene

The growing scarcity of freshwater has intensified the need for alternative water sources, which often require advanced treatments to eliminate contaminants. Among emerging pollutants, pharmaceuticals have become a significant concern due to their persistence and potential impact, making their detection essential. However, analysing these contaminants is challenging due to the extremely low concentrations at which they are present. For chemical analysis, minimal or no sample enrichment is often necessary, while bioanalysis typically requires larger sample volumes and an enrichment factor to conduct comprehensive bioassays across various endpoints. Consequently, sample preconcentration techniques for large water volumes are necessary to improve the sensitivity of subsequent toxicological experiments. In this study, a novel large volume solid-phase extraction (LV-SPE) procedure was validated and evaluated for monitoring multiple pharmaceutical compounds in water samples, while maintaining the traditional solid-phase extraction (SPE) methodology using cartridges. This method proved effective extraction and preconcentration of significant amounts of water, with recoveries between 19 % and 109 % in spiked wastewaters (except for fluvoxamine, remdesivir, tamoxifen and tetracycline, with recoveries <10 %). Furthermore, the optimization of this approach covers an expansive chemical space, enabling the capture of a diverse range of pharmaceutical compounds and enhancing the validity of toxicological studies. Bioassays conducted with Daphnia magna juveniles and Danio rerio embryos validated the method's applicability regarding optimized exposure conditions, the absence of adverse effects from SPE blanks or solvent controls and sensitivity in detecting effects across field samples. Overall, the LV-SPE approach enhances sensitivity and reliability for evaluating pharmaceutical mixtures' risks under realistic conditions.

2025-09-01·Journal of Vascular Surgery-Venous and Lymphatic Disorders

The role of venoactive compounds in the treatment of chronic venous disease

Review

作者: Nicolaides, Andrew ; Gloviczki, Monika Lecomte ; Kakkos, Stavros K ; Chuback, John ; Urbanek, Tomasz

BACKGROUND:

Chronic venous disease (CVD) is a major global health issue, affecting millions of people and contributing to significant morbidity and economic strain. The condition's pathophysiology is complex, involving both mechanical and biochemical processes that lead to venous reflux, obstruction, and chronic inflammation. This review focuses on the role of venoactive compounds (VACs), also known as venoactive drugs in Europe and other parts of the world, in managing CVD. The aim was to review the scientific evidence and to define the role of VACs within the comprehensive treatment algorithm for CVD, alongside established and well adopted interventional therapies and noninterventional therapies such as compression.

METHODS:

The review of the scientific evidence was done on VACs mechanism of action and efficacy in alleviating CVD symptoms, reducing swelling or venous edema, and improving healing of venous leg ulcers. Whenever available, systematic reviews, meta-analyses and randomized controlled trials were used. The quality of evidence assessment followed the GRADE methodology from A (high), B (moderate), to C (low to very low) quality.

RESULTS:

Venoactive drugs or compounds share similar effects, such as sealing the endothelial barrier, enhancing lymphatic drainage, reducing edema, improving venous tone, inhibiting leukocyte adhesion to vein walls/valves and inflammatory mediator release, lowering blood viscosity, and promoting red blood cell flexibility. Scientific evidence on the VACs effectiveness on CVD symptoms (pain, cramps, and heaviness) and swelling or edema have shown some variability. Micronized purified flavonoid fraction (MPFF) and Ruscus extract combined with hesperidin methyl chalcone and ascorbic acid had the highest, mostly level A, quality of evidence. In venous leg ulcers, micronized purified flavonoid fraction, sulodexide, and pentoxifylline were the most effective adjunctive treatments, with evidence level A.

CONCLUSIONS:

The existing scientific evidence provides a strong rationale for incorporating VACs into a comprehensive treatment plan for CVD, alongside established interventional therapies and noninterventional approaches like compression, to optimize patient outcomes and improve quality of life.

214

项与己酮可可碱相关的新闻（医药）

2025-07-20

·信狐药迅

两个1类新药：南京征祥玛赛洛沙韦、武汉禾元植物源重组人血清白蛋白获批上市| 新获批(7.14-7.20）

每周药品注册获批数据，分门别类呈现，一目了然。(7.14-7.20）新药上市申请药品名称企业注册分类受理号玛赛洛沙韦片南京征祥医药有限公司1CXHS2400011植物源重组人血清白蛋白注射液武汉禾元生物科技股份有限公司1CXSS2400098舒西利单抗注射液海南赛乐敏生物科技有限公司1CXSS2300072新药临床申请药品名称企业注册分类受理号YKYY029注射液北京悦康科创医药科技股份有限公司1CXHL2500569Safusidenib胶囊葆元生物医药科技(杭州)有限公司1CXHL2500473WJ47DZ片南京逸境生物医药科技有限公司1CXHL2500472WJ47DZ片南京逸境生物医药科技有限公司1CXHL2500471HRS-5041片江苏恒瑞医药股份有限公司1CXHL2500470HRS-5041片江苏恒瑞医药股份有限公司1CXHL2500469HRS-5041片江苏恒瑞医药股份有限公司1CXHL2500468HRS-5041片江苏恒瑞医药股份有限公司1CXHL2500466KW-040注射液北京凯因科技股份有限公司1CXHL2500463马来酸苏特替尼胶囊江苏迈度药物研发有限公司1CXHL2500452炔丙基半胱氨酸胶囊依诺医药(广东)有限公司1CXHL2500447炔丙基半胱氨酸胶囊依诺医药(广东)有限公司1CXHL2500446DEG6498胶囊杭州达歌生物医药科技有限公司1CXHL2500456DEG6498胶囊杭州达歌生物医药科技有限公司1CXHL2500455DEG6498胶囊杭州达歌生物医药科技有限公司1CXHL2500454NTS071片上海宇道生物技术有限公司1CXHL2500451CMS-D001片海南德镁医药科技有限责任公司1CXHL2500440纳米氧化铁注射液苏州欣影生物医药技术有限公司1CXHL2500439HRS-1893片山东盛迪医药有限公司1CXHL2500431SBK017口服溶液成都施贝康生物医药科技有限公司2.2CXHL2500477YH2201干混悬剂浙江益汉制药有限公司2.2CXHL2500438YH2201干混悬剂浙江益汉制药有限公司2.2CXHL2500437WS-019湖北午时药业股份有限公司2.2CXHL2500415GBI268注射液苏州智耀生物科技有限公司2.2CXHL2500414舒沃替尼片迪哲(江苏)医药股份有限公司2.4CXHL2500462舒沃替尼片迪哲(江苏)医药股份有限公司2.4CXHL2500461二价重组呼吸道合胞病毒疫苗(CHO 细胞)浙江三叶草生物制药有限公司1.2CXSL2500331重组三价脊髓灰质炎疫苗(Sf-RVN细胞)康希诺生物股份公司1.2CXSL2500324注射用HDM2012杭州中美华东制药有限公司1CXSL2500483注射用HS-20093上海翰森生物医药科技有限公司1CXSL2500380SIBP-A16 注射液上海生物制品研究所有限责任公司1CXSL2500379注射用GB268嘉和生物药业有限公司1CXSL2500372IBI3011信达生物制药(苏州)有限公司1CXSL2500369注射用RC278荣昌生物制药(烟台)股份有限公司1CXSL2500368注射用VDJ006北京伟德杰生物科技有限公司1CXSL2500363注射用DB-1305映恩生物制药(苏州)有限公司1CXSL2500362注射用DB-1311映恩生物制药(苏州)有限公司1CXSL2500361BAT4406F注射液百奥泰生物制药股份有限公司1CXSL2500349注射用重组病毒巨噬细胞炎性蛋白广州弘润生物科技有限公司1CXSL2500346HCL001细胞注射液上海慧存医疗科技有限公司1CXSL2500323仿制药申请药品名称企业注册分类受理号注射用盐酸头孢替安/氯化钠注射液湖南科伦制药有限公司3CYHS2501904复合磷酸氢钾注射液济南康桥医药科技有限公司3CYHS2501851盐酸溴己新口服溶液合肥远志医药科技开发有限公司3CYHS2501814复方聚乙二醇电解质散(II)湖南普道医药技术有限公司3CYHS2404347盐酸普罗帕酮注射液江苏神龙药业有限公司3CYHS2402489腺苷钴胺胶囊杭州沐源生物医药科技有限公司3CYHS2401029硫酸沙丁胺醇口服溶液浙江恒研医药科技有限公司3CYHS2400946葡萄糖酸钙注射液石家庄四药有限公司3CYHS2400869异烟肼注射液沈阳红旗制药有限公司3CYHS2400870盐酸麻黄碱注射液成都苑东生物制药股份有限公司3CYHS2400825法莫替丁注射液湖南柏齐鹤药物研发有限公司3CYHS2400817腺苷钴胺胶囊湖南千金湘江药业股份有限公司3CYHS2400793美索巴莫注射液西洲医药科技(浙江)有限公司3CYHS2400686盐酸曲唑酮片河北龙海药业有限公司3CYHS2400436米诺地尔搽剂乐福思健康产业股份公司3CYHS2400413米诺地尔搽剂乐福思健康产业股份公司3CYHS2400411盐酸去氧肾上腺素注射液珠海前列药业有限公司3CYHS2400406盐酸去氧肾上腺素注射液珠海前列药业有限公司3CYHS2400404盐酸丙卡特罗口服溶液江苏广承药业有限公司3CYHS2400259腺苷钴胺胶囊浙江美迪深生物医药有限公司3CYHS2400254盐酸丙卡特罗口服溶液岳阳新华达制药有限公司3CYHS2400185复合磷酸氢钾注射液浙江高跖医药科技股份有限公司3CYHS2400139异烟肼注射液辽宁海神联盛制药有限公司3CYHS2400095己酮可可碱缓释片浙江赛默制药有限公司3CYHS2400115盐酸溴己新口服溶液河南上恒医药科技有限公司3CYHS2400065盐酸溴己新口服溶液河南上恒医药科技有限公司3CYHS2400066磷酸奥司他韦颗粒海南涛生医药科技研究院有限公司3CYHS2400033碳酸司维拉姆干混悬剂昆明贝克诺顿制药有限公司3CYHS2400037卡络磺钠注射液河北欣瑞未来科技有限公司3CYHS2303552注射用赖氨匹林海南天盛保和生物科技有限公司3CYHS2303496膦甲酸钠注射液华夏生生药业(北京)有限公司3CYHS2303384富马酸酮替芬滴眼液石家庄四药有限公司3CYHS2303334硫辛酸片福安药业集团烟台只楚药业有限公司3CYHS2303304硫辛酸片福安药业集团烟台只楚药业有限公司3CYHS2303302聚乙烯醇滴眼液浙江视方极医药科技有限公司3CYHS2303155盐酸纳洛酮注射液重庆中创科医药有限公司3CYHS2303080盐酸纳洛酮注射液重庆中创科医药有限公司3CYHS2303079盐酸拉贝洛尔氯化钠注射液北京柏雅联合药物研究所有限公司3CYHS2302925法莫替丁注射液中山万汉制药有限公司3CYHS2302780葡萄糖酸钙氯化钠注射液安徽丰原药业股份有限公司淮海药厂3CYHS2302661葡萄糖酸钙氯化钠注射液安徽丰原药业股份有限公司淮海药厂3CYHS2302660吲哚布芬片北京伟林恒昌医药科技有限公司3CYHS2302426依帕司他片广州仁恒医药科技股份有限公司3CYHS2302333盐酸伐地那非片山东华铂凯盛生物科技有限公司4CYHS2402999乳果糖口服溶液河南合智医药科技有限公司4CYHS2402771妥布霉素滴眼液扬州中宝药业股份有限公司4CYHS2402292氧(液态)浙江中龙气体科技有限公司4CYHS2402148沙库巴曲缬沙坦钠片湖南千金协力药业有限公司4CYHS2401748聚乙烯醇滴眼液浙江百代医药科技有限公司4CYHS2401649注射用阿糖胞苷仁合熙德隆药业有限公司4CYHS2401365注射用阿糖胞苷仁合熙德隆药业有限公司4CYHS2401363阿仑膦酸钠片山东华铂凯盛生物科技有限公司4CYHS2401153枸橼酸西地那非片河南中帅医药科技股份有限公司4CYHS2400864枸橼酸西地那非口腔崩解片济南高华制药有限公司4CYHS2400859精氨酸布洛芬颗粒中山万汉制药有限公司4CYHS2400765精氨酸布洛芬颗粒中山万汉制药有限公司4CYHS2400764替米沙坦氨氯地平片(II)湖南慧泽生物医药科技有限公司4CYHS2400459利奥西呱片江苏华阳制药有限公司4CYHS2400370利奥西呱片江苏华阳制药有限公司4CYHS2400369利奥西呱片江苏华阳制药有限公司4CYHS2400368醋酸加尼瑞克注射液成都圣诺生物制药有限公司4CYHS2400298盐酸曲美他嗪缓释片广州白云山医药集团股份有限公司白云山制药总厂4CYHS2400195甲磺酸雷沙吉兰片苏中药业集团股份有限公司4CYHS2400180硫酸阿巴卡韦片上海迪赛诺医药集团股份有限公司4CYHS2303477ω-3脂肪酸乙酯90软胶囊浙江医药股份有限公司新昌制药厂4CYHS2303154硫糖铝混悬凝胶云南积大生物科技有限公司4CYHS2302301二十碳五烯酸乙酯软胶囊四川科伦药业股份有限公司4CYHS2301645盐酸帕罗西汀肠溶缓释片北京世桥生物制药有限公司4CYHS2301313利斯的明透皮贴剂宜昌人福药业有限责任公司4CYHS2300811利斯的明透皮贴剂宜昌人福药业有限责任公司4CYHS2300810盐酸达泊西汀片植恩生物技术股份有限公司4CYHS2201518国;CYHS2201518舒更葡糖钠注射液江苏万高药业股份有限公司4CYHS2101401国;CYHS2101401舒更葡糖钠注射液江苏万高药业股份有限公司4CYHS2101402国;CYHS2101402瑞卢戈利片江苏联环药业股份有限公司3CYHL2500092布立西坦口服溶液山东达因海洋生物制药股份有限公司3CYHL2500091克霉唑阴道片浙江高跖医药科技股份有限公司4CYHL2500090倍氯米松福莫特罗吸入气雾剂合肥力成药业有限公司4CYHL2500088艾美赛珠单抗注射液南京正大天晴制药有限公司3.3CXSL2500357艾美赛珠单抗注射液南京正大天晴制药有限公司3.3CXSL2500356HWS111注射液湖北生物医药产业技术研究院有限公司3.3CXSL2500351进口申请药品名称企业注册分类受理号司美格鲁肽注射液Novo Nordisk Pharma AG2.2JXSS2400069司美格鲁肽注射液Novo Nordisk Pharma AG2.2JXSS2400068Rilzabrutinib片Sanofi-Aventis Recherche & Developpement1JXHL2500112AZD9833片ASTRAZENECA AB1JXHL2500107TQJ230注射液Novartis Pharma AG1JXHL2500103注射用KSP-1007-05Sumitomo Pharma Co., Ltd.1JXHL2500087AZD9793AstraZeneca AB1JXSL2500075Mezagitamab注射剂Takeda Development Center Americas, Inc.1JXSL2500067VHB937注射用浓溶液Novartis Pharma AG1JXSL2500065RisankizumabAbbVie Inc.2.1JXSL2500072RisankizumabAbbVie Inc.3.1JXSL2500073中药相关申请药品名称企业注册分类受理号化瘀解热颗粒四川省中医药转化医学中心1.1CXZL2500025枇杷清肺颗粒神威药业集团有限公司3.1CXZS2400032枇杷清肺饮颗粒天士力医药集团股份有限公司3.1CXZS2400002注：橙色字体部分结论为不批准或收到通知件；

疫苗申请上市

2025-06-26

·EINPresswire

Pentoxifylline Fails to Improve Survival in Alcohol-Associated Hepatitis with Kidney Injury

Researchers found no significant benefit in short- or long-term mortality outcomes with pentoxifylline use. CHINA, June 26, 2025 / EINPresswire.com / -- Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney injury (AKI), a complication that substantially worsens prognosis. Corticosteroids are currently the only treatment shown to offer a modest short-term survival benefit in selected patients. Pentoxifylline, a phosphodiesterase inhibitor with anti-tumor necrosis factor alpha (TNF-α) properties, has been proposed as a potential alternative, especially for patients with contraindications to steroids or coexisting AKI. However, evidence supporting its efficacy has been inconsistent and regionally variable. To clarify the clinical utility of pentoxifylline in this setting, Idalsoaga et al. conducted a retrospective, multicenter registry study across 20 centers from eight countries. The study was published in eGastroenterology . The study included 525 patients diagnosed with sAH and AKI between 2009 and 2019. The primary outcome was all-cause mortality, with liver transplantation considered as a competing event. Main results include: (1) Survival rates at 90 days were 46.2% in the pentoxifylline group versus 49.8% in the control group. (2) Multivariable Cox regression showed that pentoxifylline use was not significantly associated with improved survival. (3) Key predictors of mortality were: older age, higher MELD score at admission, and requirement for renal replacement therapy. In addition, a secondary exploratory analysis focusing on patients with serum creatinine ≥1.5 mg/dL reaffirmed these findings. Again, pentoxifylline use did not improve survival at any time point, including 30, 90, or 180 days. The results of this large real-world cohort study confirm that pentoxifylline offers no mortality benefit in sAH patients with concurrent AKI. This is consistent with previous studies and meta-analyses that have cast doubt on the efficacy of pentoxifylline in alcoholic hepatitis overall. Although pentoxifylline has shown renal protective effects in animal models and other clinical contexts (e.g., diabetic nephropathy, cardiac surgery), these mechanisms may not sufficiently counteract the complex inflammatory and hemodynamic disturbances seen in sAH with AKI. The high rates of multiorgan failure and infection-related deaths in this cohort highlight the multifactorial pathogenesis of mortality in these patients. This study stands out for its large, diverse international cohort, and rigorous statistical approach. However, the retrospective design introduces inherent limitations such as missing data and potential confounding. Nearly half of the records lacked infection data, and the precise timing, dosing, and duration of pentoxifylline therapy were unavailable, which should be explored in the future. The clear absence of benefit from pentoxifylline suggests a pressing need for novel therapies in sAH, particularly for those with AKI who are often excluded from corticosteroid treatment. Potential strategies may include: (1) Targeting specific inflammatory pathways (e.g., IL-1, gut-liver axis); (2) Microbiota-modulating interventions; (3) Plasma exchange; (4) Trials of combination therapy (e.g., corticosteroids + novel agents). Moreover, early detection of renal dysfunction and proactive infection management remain critical components of supportive care. In conclusion, pentoxifylline does not improve survival in patients with sAH and AKI. These findings challenge current regional practices where pentoxifylline remains in use and underscore the need to re-evaluate its role in clinical guidelines. Future research should pivot toward novel, mechanism-based therapies to address the unmet needs of this high-risk population. *** About eGastroenterology eGastroenterology is a new, open-access, and open peer-reviewed BMJ Journal, which focuses on basic, clinical, translational, and evidence-based medicine research in all areas of gastroenterology (including hepatology, pancreatology, esophagology, and gastrointestinal surgery). eGastroenterology is now indexed by PubMed, Scopus, CAS, DOAJ, Dimensions, OpenAlex, ROAD, and COPE, with more to come! For more information, please visit: egastroenterology.bmj.com and follow us on Twitter (@eGastro_BMJ). Menghan Gao eGastroenterology +86 431 8878 2545 egastro@jlu.edu.cn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床结果

2025-06-22

·信狐药迅

康希诺-国产13价肺炎球菌多糖结合疫苗上市| 新获批(6.16-6.22）

每周药品注册获批数据，分门别类呈现，一目了然。(6.16-6.22）新药上市申请药品名称企业注册分类受理号13价肺炎球菌多糖结合疫苗(CRM197,TT载体)康希诺生物股份公司2.2CXSS2400020新药临床申请药品名称企业注册分类受理号HRS-8829注射用浓溶液北京盛迪医药有限公司1CXHL2500379艾本那肽注射液常山凯捷健生物药物研发(河北)有限公司1CXHL2500378注射用TFX05-01浙江扬厉医药技术有限公司1CXHL2500373TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2500371TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2500370DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500376DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500375DAT-1604片北京丹擎医药科技有限公司1CXHL2500364DAT-1604片北京丹擎医药科技有限公司1CXHL2500363WEYZ-1乳膏南京韦尔优众医药有限公司1CXHL2500365177Lu-NRT6020注射液成都纽瑞特医疗科技股份有限公司1CXHL250035968Ga-NRT6020注射液成都纽瑞特医疗科技股份有限公司1CXHL2500358VCT220片成都闻泰医药科技有限公司1CXHL2500355VCT220片成都闻泰医药科技有限公司1CXHL2500354VCT220片成都闻泰医药科技有限公司1CXHL2500353AOD113408注射液成都奥达生物科技有限公司1CXHL2500339EDP167注射液亿腾医药(珠海)有限公司1CXHL2500336JKN2301干混悬剂健康元药业集团股份有限公司1CXHL2500327EP-0203XR成都苑东生物制药股份有限公司2.3CXHL2500333舒沃替尼片迪哲(江苏)医药股份有限公司2.4CXHL2500374枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500351枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500350枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500349枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500348ZHCX002九华华源药业股份有限公司2.4CXHL2500313流感病毒裂解疫苗(BK-01佐剂)长春百克生物科技股份公司3.2CXSL2500239SCTB39-1注射液神州细胞工程有限公司1CXSL2500364AI-081注射液南京昂科免疫生物医药有限公司1CXSL2500304PM1300注射用冻干制剂珠海普米斯生物科技有限公司1CXSL2500290注射用HY0001a四川汇宇海玥医药科技有限公司1CXSL2500294LNF2102注射液山东新时代药业有限公司1CXSL2500287注射用QLS32015齐鲁制药有限公司1CXSL2500285注射用LY4101174礼来苏州制药有限公司1CXSL2500272注射用ZG006苏州泽璟生物制药股份有限公司1CXSL2500279注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2500278CM512注射液康诺亚生物医药科技(成都)有限公司1CXSL2500275ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500264ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500263IMC-003宜明凯尔生物医药技术(上海)有限公司1CXSL2500261HD006细胞华道(上海)生物医药有限公司1CXSL2500251QL2109注射液齐鲁制药有限公司2.2CXSL2500284仿制药申请药品名称企业注册分类受理号盐酸苯海拉明注射液华夏生生药业(北京)有限公司3CYHS2501576复方电解质注射液(V)河北天成药业股份有限公司3CYHS2400745法莫替丁注射液海南全星制药有限公司3CYHS2400674氯化钙注射液华夏生生药业(北京)有限公司3CYHS2400602尼麦角林片浙江赛默制药有限公司3CYHS2400518己酮可可碱注射液辰欣药业股份有限公司3CYHS2400498法莫替丁注射液东阳祥昇医药科技有限公司3CYHS2400342美洛昔康注射液石药集团中诺药业(石家庄)有限公司3CYHS2400303阿奇霉素颗粒重庆莱美药业股份有限公司3CYHS2400199盐酸西替利嗪口服溶液福建海西新药创制股份有限公司3CYHS2303555注射用盐酸罗沙替丁醋酸酯山东豪瑞恩制药有限公司3CYHS2303400醋酸葡萄糖维持液仁合益康集团有限公司3CYHS2303177醋酸葡萄糖维持液仁合益康集团有限公司3CYHS2303176布洛芬注射液陕西丽彩药业有限公司3CYHS2303063布洛芬注射液陕西丽彩药业有限公司3CYHS2303062重酒石酸间羟胺注射液弘和制药有限公司3CYHS2302971硫辛酸片浙江恒研医药科技有限公司3CYHS2302913醋酸钙片青岛百洋制药有限公司3CYHS2302887地氯雷他定口服溶液湖南嘉恒制药有限公司3CYHS2302849己酮可可碱注射液浙江北生药业汉生制药有限公司3CYHS2302843异烟肼注射液海南秋实医药科技有限公司3CYHS2302710氨溴特罗口服溶液南京易腾药物研究院有限公司3CYHS2302510磷酸奥司他韦干混悬剂恒昌(广州)新药研究有限公司3CYHS2302257地塞米松磷酸钠注射液汇禹远和(海南)药业有限公司3CYHS2300998枸橼酸铋钾片浙江京新药业股份有限公司4CYHS2402389非诺贝特酸胆碱缓释胶囊湖南九典制药股份有限公司4CYHS2401389阿司匹林肠溶片浙江易泽达医药科技有限公司4CYHS2401356贝前列素钠片山东百诺医药股份有限公司4CYHS2401345达肝素钠注射液辰欣药业股份有限公司4CYHS2401232达肝素钠注射液辰欣药业股份有限公司4CYHS2401231盐酸达泊西汀片浙江北生药业汉生制药有限公司4CYHS2400915盐酸达泊西汀片昆山培力药品有限公司4CYHS2400863复方托吡卡胺滴眼液山东辰欣佛都药业股份有限公司4CYHS2400860盐酸氨溴索口服溶液黑龙江澳利达奈德制药有限公司4CYHS2400828甲氨蝶呤注射液江苏奥赛康药业有限公司4CYHS2400815甲氨蝶呤注射液江苏奥赛康药业有限公司4CYHS2400814比索洛尔氨氯地平片天大药业(珠海)有限公司4CYHS2400634丙酸氟替卡松乳膏重庆华邦制药有限公司4CYHS2400596夫西地酸乳膏重庆华邦制药有限公司4CYHS2400560注射用唑来膦酸浓溶液广州市联瑞制药有限公司4CYHS2400505盐酸达泊西汀片郑州德迈药业有限公司4CYHS2400522注射用硫酸艾沙康唑山西德元堂药业有限公司4CYHS2400392盐酸氨溴索口服溶液湖北凯纳药业有限公司4CYHS2400216盐酸氨溴索口服溶液湖北凯纳药业有限公司4CYHS2400215磷霉素氨丁三醇颗粒苏州二叶制药有限公司4CYHS2400128西甲硅油乳剂成都倍特得诺药业有限公司4CYHS2400109布洛芬混悬液河南省尤里卡生物科技有限公司4CYHS2400070布洛芬混悬液河南省尤里卡生物科技有限公司4CYHS2400069瑞巴派特片东阳祥昇医药科技有限公司4CYHS2400078蒙脱石散郑州泰丰制药有限公司4CYHS2303493铝碳酸镁咀嚼片太康海恩药业有限公司4CYHS2303433他氟前列素滴眼液江苏安必生制药有限公司4CYHS2303258吸入用布地奈德混悬液江苏西普拉制药有限公司4CYHS2303217富马酸伏诺拉生片宁波科尔康美诺华药业有限公司4CYHS2303018富马酸伏诺拉生片宁波科尔康美诺华药业有限公司4CYHS2303017布南色林片河北龙海药业有限公司4CYHS2302617左卡尼汀口服溶液吉林省辉南长龙生化药业股份有限公司4CYHS2301985唑来膦酸注射液吉林四长制药有限公司4CYHS2300987盐酸乌拉地尔注射液北京民康百草医药科技有限公司4CYHS2300535四价流感病毒裂解疫苗复星雅立峰(大连)生物制药有限公司3.3CXSS2200083利妥昔单抗注射液山东新时代药业有限公司3.3CXSS2400015达普司他片齐鲁制药(海南)有限公司3CYHL2500085达普司他片齐鲁制药(海南)有限公司3CYHL2500084达普司他片齐鲁制药(海南)有限公司3CYHL2500083达普司他片齐鲁制药(海南)有限公司3CYHL2500082镥[177Lu]氧奥曲肽注射液迈得诺医疗科技集团有限公司3CYHL2500076盐酸达克罗宁局部溶液剂深圳珐玛易药品科技有限公司3CYHL2500073沙美特罗替卡松吸入粉雾剂杭州知兴制药有限公司4CYHL2500068吸附破伤风疫苗北京智飞绿竹生物制药有限公司3.3CXSL2500250流感病毒裂解疫苗陕西昆秦生物科技有限公司3.3CXSL2500243人生长激素注射液亿帆医药(上海)有限公司3.3CXSL2500289进口申请药品名称企业注册分类受理号盐酸达利雷生片Idorsia Pharmaceuticals Deutschland GmbH5.1JXHS2400050盐酸达利雷生片Idorsia Pharmaceuticals Deutschland GmbH5.1JXHS2400049左甲状腺素钠片Aristo Pharma GmbH5.2JYHS2400034左甲状腺素钠片Aristo Pharma GmbH5.2JYHS2400033重酒石酸间羟胺注射液Wockhardt Bio Pty Ltd.5.2JYHS2400006注射用醋酸卡泊芬净Gland Pharma Limited5.2JYHS2300034骨化三醇软胶囊Strides Pharma Global Pte Limited5.2JYHS2200010国;JYHS2200010骨化三醇软胶囊Strides Pharma Global Pte Limited5.2JYHS2200009国;JYHS2200009Casdatifan 片Arcus Biosciences, Inc.1JXHL2500076奥拉帕利片AstraZeneca AB2.4JXHL2500083奥拉帕利片AstraZeneca AB2.4JXHL2500082ABBV-324注射用粉末AbbVie Inc.1JXSL2500055MEDI5752AstraZeneca AB1JXSL2500056Isatuximab注射液(皮下注射)Sanofi-Aventis Recherche & Développement2.1JXSL2500053Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500052Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500051中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

疫苗申请上市上市批准

100 项与己酮可可碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00501	己酮可可碱	C04AD03	DB00806

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
间歇性跛行	澳大利亚	Clinect Pty Ltd.	2001-12-14
外周动脉闭塞性疾病	美国	Validus Pharmaceuticals LLC	1984-08-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
白塞病/贝赫切特综合征	临床2期	英国	Poolbeg Pharma Plc	2024-04-30
弱精子症	临床2期	西班牙	-	2017-05-08
获得性免疫缺陷综合征	临床1期	美国	Hoechst Marion Roussel, Inc.	2001-08-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05708248 (Pubmed \| Postgrad Med)	N/A	贫血 \| 血液透析并发症 HIF-2α \| TGF-β1 \| hs.CRP	80	Pentoxifylline 400 mg	壓鏇遞糧蓋襯鬱鏇築憲(獵鹽遞壓夢觸築網積鏇) = 鬱襯餘憲艱繭壓衊鏇餘製餘鹹網襯膚願築壓繭 (積選鬱壓製蓋顧築膚積, 2.01 ~ 10.09) 更多	积极	2024-11-10
NCT02592863 (CTgov)	N/A	眩晕 \| 头晕 \| 平衡失调	26	Pentoxifylline (Pentoxifylline)	膚窪鹹顧獵淵蓋遞膚範(願艱膚遞醖鬱範齋憲遞) = 鹹餘蓋膚鏇範淵顧顧糧顧壓簾壓醖鹽製夢網蓋 (鹹獵淵遞觸窪鑰簾獵糧, 16.236) 更多	-	2024-10-15
				Placebo (Placebo)	膚窪鹹顧獵淵蓋遞膚範(願艱膚遞醖鬱範齋憲遞) = 願憲齋獵鏇獵選夢繭構顧壓簾壓醖鹽製夢網蓋 (鹹獵淵遞觸窪鑰簾獵糧, 22.825) 更多
NCT02451774 (Pubmed \| Front Oncol)	临床2/3期	急性淋巴细胞白血病	-	Pentoxifylline	衊衊鑰構築觸網繭簾鏇(顧範簾壓醖範積獵顧糧) = 鏇繭簾夢糧淵鏇窪網餘願範觸鏇願顧鹹蓋蓋鹹 (構願憲網餘獵膚鏇膚艱 ) 更多	积极	2024-10-03
				Placebo	衊衊鑰構築觸網繭簾鏇(顧範簾壓醖範積獵顧糧) = 襯餘膚鬱遞窪膚窪顧鹹願範觸鏇願顧鹹蓋蓋鹹 (構願憲網餘獵膚鏇膚艱 ) 更多
NCT05487755 (Pubmed) 人工标引	临床3期	糖尿病肾病辅助	90	Tadalafil 20 mg	構鬱顧選選膚淵範範襯(鬱製窪廠遞齋觸襯觸窪) = 窪遞願願廠獵積構淵顧觸顧醖鬱觸構窪構積顧 (製築鏇糧製餘繭蓋簾網 )	积极	2024-06-24
				Pentoxifylline 400 mg	構鬱顧選選膚淵範範襯(鬱製窪廠遞齋觸襯觸窪) = 窪蓋膚醖觸鑰積範淵製觸顧醖鬱觸構窪構積顧 (製築鏇糧製餘繭蓋簾網 )
NCT01774487 (CTgov)	临床2期	胆道闭锁	17	Pentoxifylline (Pentoxifylline - Group 1)	齋網構鬱壓鏇衊淵選顧 = 鹽窪願願廠廠鏇膚窪齋選觸夢鏇積鏇範鬱鏇壓 (範鹽積選蓋範積蓋積獵, 製顧繭遞築鏇鬱範築膚 ~ 獵鹹襯夢夢糧鹹築鏇鏇) 更多	-	2023-10-12
				Pentoxifylline (Pentoxifylline - Group 2)	齋網構鬱壓鏇衊淵選顧 = 鑰製憲積醖構繭鑰醖窪選觸夢鏇積鏇範鬱鏇壓 (範鹽積選蓋範積蓋積獵, 餘範齋築衊簾壓遞獵壓 ~ 淵製齋簾醖範壓願鬱鹹) 更多
ASTRO2023	N/A	肺炎	-	Pentoxifylline and Vitamin E	醖積獵鹹鏇觸餘齋餘鹽(遞夢選構觸範構繭鬱簾) = 鹹觸齋廠鑰齋遞衊齋顧築鬱衊鏇範淵簾壓齋鏇 (構齋鏇網積齋鏇淵簾簾 )	-	2023-10-01
NCT01508221 (CTgov)	临床2期	辐射损伤 \| 脑转移瘤	31	Vitamin E+Trental	襯餘網齋衊鑰鏇範糧繭 = 築鬱夢遞鹹憲餘艱鏇鏇艱築鑰齋鹽鬱鏇選襯艱 (醖膚鹹蓋網蓋繭夢餘構, 鑰淵積觸鏇憲鹹淵網鏇 ~ 淵齋選簾衊築廠醖艱鏇) 更多	-	2023-09-14
NCT03830164 (CTgov)	临床2期	勃起功能障碍 \| 前列腺腺癌	14	statin+Atorvastatin+Pentoxyfilline+Vitamin E (Cohort 1)	積壓繭觸壓糧構鬱糧願 = 簾醖糧蓋醖鏇網窪鑰糧鹹糧願壓獵鏇艱獵繭醖 (遞積鬱獵獵糧蓋膚獵鏇, 蓋膚築壓壓鹹餘鬱簾獵 ~ 憲範淵製蓋築廠鹹齋齋) 更多	-	2023-04-03
				Atorvastatin+Pentoxyfilline+Vitamin E (Cohort 2)	積壓繭觸壓糧構鬱糧願 = 襯願積窪醖鑰網製醖醖鹹糧願壓獵鏇艱獵繭醖 (遞積鬱獵獵糧蓋膚獵鏇, 淵網顧膚網網夢鏇衊選 ~ 壓鹹鑰壓築蓋夢醖鏇觸) 更多
RTHP-01 (SNO2019)	N/A	-	48	Pentoxifylline + Vitamin E	顧膚選膚齋齋積窪觸觸(齋觸糧壓醖餘齋蓋壓鏇) = 3 patients stopped Ptx + VitE due to reported side effects 鏇網製窪壓夢鹹鏇觸夢 (鹽選鏇艱醖壓繭餘衊淵 )	积极	2019-11-11
ERS2019	N/A	结节病 TNF	44	Pentoxifylline	遞鹽膚範簾襯廠獵觸網(壓範壓醖淵窪醖衊顧壓) = 鹹夢艱衊顧積廠糧襯廠糧顧壓築壓鹹構窪繭選 (醖淵鑰築齋鹹獵鹽餘積 )	积极	2019-09-28